Brad Margus MBA

Brad Margus is co-founder and CEO of Cerevance, a new drug discovery company focused on brain diseases with sites in Massachusetts and the United Kingdom. In 2013, Margus started Genome Bridge, a non-profit subsidiary of the Broad Institute of Harvard and M.I.T., to build a computational platform for sharing genomic and clinical data. He previously co-founded Envoy Therapeutics in 2009, serving as Chief Executive Officer prior to its acquisition by Takeda in 2012. Earlier, Mr. Margus co-founded Perlegen Sciences and served as its Vice Chairman and Chief Executive Officer.